Evidence map›Paper›PMID 32997210›Full record

ArticleInvestigational new drugs2021

Discovery of oxyepiberberine as a novel tubulin polymerization inhibitor and an anti-colon cancer agent against LS-1034 cells.

Hanbing Ning, Wenquan Lu, Qiaoyu Jia, Jingyun Wang, Tingting Yao, Shuai Lv, Yingxia Li, Hongtao Wen

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. An Updated and Comprehensive Review ofMolecules (Basel, Switzerland) · 2026
    Review
  2. Article
  3. Article
  4. Current Advances inFrontiers in pharmacology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Hanbing NingDepartment of Digestive Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. nhbing419@126.com.
Wenquan LuDepartment of Digestive Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Qiaoyu JiaDepartment of Digestive Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Jingyun WangDepartment of Digestive Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Tingting YaoDepartment of Digestive Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Shuai LvDepartment of Digestive Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Yingxia LiDepartment of Digestive Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Hongtao WenDepartment of Digestive Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coptis chinensis Franch. has been extensively used in traditional Chinese medicine. The chemical structure of oxyepiberberine, as an alkaloid isolated from Coptis chinensis Franch., has been previously studied. However, anti-cancer effects and underlying mechanisms of oxyepiberberine need to be explored. This study aimed to investigate the anti-cancer effects and underlying mechanisms of oxyepiberberine on LS-1034 human colon cancer cells. The anti-proliferative effects of six derivatives of oxyepiberberine on colon cancer cells were assessed. Among six derivatives, oxyepiberberine showed the greatest anti-proliferative effect on LS-1034 cells with an IC

Indexed as

AnimalsAntineoplastic AgentsApoptosisBerberine AlkaloidsCell Line, TumorCell ProliferationColonic NeoplasmsCoptis chinensisHumansInhibitory Concentration 50MiceMice, NudeTubulin ModulatorsXenograft Model Antitumor AssaysAntineoplastic AgentsBerberine AlkaloidsoxyepiberberineTubulin ModulatorsApoptosisColon cancer xenograftLS-1034 cellsOxyepiberberineTubulin polymerization

Identifiers

PMID32997210
OpenAlexW3090911670

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.